U.S. markets closed
  • S&P Futures

    3,972.50
    +2.25 (+0.06%)
     
  • Dow Futures

    33,870.00
    -1.00 (-0.00%)
     
  • Nasdaq Futures

    11,622.25
    +6.00 (+0.05%)
     
  • Russell 2000 Futures

    1,836.40
    +3.60 (+0.20%)
     
  • Crude Oil

    76.83
    -0.41 (-0.53%)
     
  • Gold

    1,740.00
    -0.30 (-0.02%)
     
  • Silver

    20.93
    +0.02 (+0.10%)
     
  • EUR/USD

    1.0352
    +0.0007 (+0.07%)
     
  • 10-Yr Bond

    3.7030
    +0.0120 (+0.33%)
     
  • Vix

    22.21
    +1.71 (+8.34%)
     
  • GBP/USD

    1.1973
    +0.0008 (+0.07%)
     
  • USD/JPY

    139.1100
    +0.2090 (+0.15%)
     
  • BTC-USD

    16,187.89
    -55.26 (-0.34%)
     
  • CMC Crypto 200

    379.61
    -0.68 (-0.18%)
     
  • FTSE 100

    7,474.02
    -12.65 (-0.17%)
     
  • Nikkei 225

    28,037.49
    -125.34 (-0.45%)
     

PLx Pharma Inc. (NASDAQ:PLXP) drops to US$21m and insiders who purchased earlier this year lose another US$52k

Insiders who acquired US$65k worth of PLx Pharma Inc.'s (NASDAQ:PLXP) stock at an average price of US$3.66 in the past 12 months may be dismayed by the recent 17% price decline. Insiders invest with the hopes of seeing their money grow in value over time. However, as a result of recent losses, their initial investment is now only worth US$14k, which is not what they expected.

Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.

View our latest analysis for PLx Pharma

PLx Pharma Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider purchase was by CFO and Head of Manufacturing & Supply Chain Rita O'Connor for US$50k worth of shares, at about US$3.66 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being US$0.76). While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.

In the last twelve months PLx Pharma insiders were buying shares, but not selling. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

PLx Pharma is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Does PLx Pharma Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Our data indicates that PLx Pharma insiders own about US$1.3m worth of shares (which is 6.1% of the company). Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!

What Might The Insider Transactions At PLx Pharma Tell Us?

The fact that there have been no PLx Pharma insider transactions recently certainly doesn't bother us. On a brighter note, the transactions over the last year are encouraging. We'd like to see bigger individual holdings. However, we don't see anything to make us think PLx Pharma insiders are doubting the company. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Every company has risks, and we've spotted 5 warning signs for PLx Pharma (of which 2 are significant!) you should know about.

But note: PLx Pharma may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here